Evolving Strategies in Adjuvant HER2+ Breast Cancer
Experts analyze adjuvant therapy based on preoperative responses. The discussion unveils standard practices, recent KATHERINE trial data, and considerations for residual disease, offering profound insights into tailoring treatment for improved outcomes.
EP: 1.Evolving HER2+ Breast Cancer Care: Neo-Adjuvant Strategies and Treatment Goals
EP: 2.Neoadjuvant Approaches in HER2+ Breast Cancer
EP: 3.HER2+ Breast Cancer: Anthracycline Considerations
EP: 4.Subcutaneous HER2+ Breast Cancer Treatment Trends
EP: 5.Adjuvant Strategies in HER2+ Brest Cancer: Timing and Tailoring
EP: 6.Evolving Strategies in Adjuvant HER2+ Breast Cancer
EP: 7.Exploring Therapeutic Avenues in HER2+ Breast Cancer
EP: 8.Metastatic HER2+ Breast Cancer: Current Strategies and Ongoing Trials
EP: 9.Navigating Second-Line Choices in HER2+ Breast Cancer
EP: 10.Decoding HER2+ Breast Cancer: Challenges in Brain Metastases
EP: 11.Navigating HER2+ Brain Metastases: Emerging Insights
EP: 12.HER2+ Breast Cancer Treatment Dynamics and Challenges
EP: 13.Navigating Treatment Challenges in HER2+ Breast Cancer
EP: 14.Insights and Challenges in Advancing HER2+ Breast Cancer Care
This is a video synopsis/summary of a Peer Exchange involving Joyce O’Shaughnessy, MD; Priyanka Sharma, MD; Claudine Isaacs, MD; Heather McArthur, MD; and Hope S. Rugo, MD, FASCO.
O’Shaughnessy seeks an update on adjuvant therapy based on preoperative responses, prompting Isaacs to share insights. The standard of care for patients with residual disease involves the KATHERINE regimen with T-DM1 (trastuzumab emtansine), showing significant benefits in progression-free and overall survival (OS). McArthur further discusses the impressive data from the KATHERINE trial, which revealed a substantial increase in invasive disease-free survival and an overall survival advantage after 8.4 years of follow-up. Notably, the trial demonstrated consistent benefits across various patient subgroups.
O’Shaughnessy expresses emotional astonishment at the separation in survival curves, emphasizing the profound impact of T-DM1. McArthur underscores the need for continued research, acknowledging that despite the substantial progress, 1 in 5 women with residual disease still experiences recurrence. The discussion highlights the importance of tailoring therapy based on response, considering factors such as nodal involvement, and reflects on the evolving landscape of HER2-positive breast cancer treatment.
Video synopsis is AI-generated and reviewed by OncLive® editorial staff.
